Replies to post #433553 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

A "prevention trial" won't be needed.

We won’t have a prevention trial for years

You are certainly welcome to have that perception. It's probably true.

But the real "trial" of the disease prophylaxis and antiaging properties of the Anavex molecules in humans will be self-evident when blarcamesine is used to treat a CNS disease; most likely when patients with Alzheimer's get treated.

First, it will be noted that the drug does, indeed, halt or reverse the cognitive decline of Alzheimer's. But in Alzheimer's patients being successfully treated with blarcamesine it will be incidentally discovered that not only are Alzheimer's symptoms put in remission but normal aging processes or pathologies are slowed or reversed. It will be discovered that not only does blarcamesine successfully treat Alzheimer's, but at the same time a diversity of other geriatric health conditions subside or are delayed.

The profound Anavex prophylaxis factor; something that won't be missed by attending physicians (who, like Dr. Hagerman, will then want the drug for themselves).